Stroke Research & Data

Stroke Research

The TESLA trial: Thrombectomy for Emergent Salvage of Large Anterior Circulation Stroke

Primary Investigator: Sushrut Dharmadhikari M.D.

National Clinical Trials Identifier: NCT03805308

Clinical Trial Link

Enrollment Status: Open

Clinical Trial Summary:

Phase III

Funding Agency/Sponsor: Mercy Health Ohio, Genentech, Cerenovus, Medtronic, Penumbra, Stryker

Disease: Ischemic Stroke

Enrollment/Eligibility

Inclusion Criteria:

  1. 18 to 85 years of age
  2. Presenting with symptoms consistent with an acute ischemic stroke
  3. Imaging evidence of an anterior circulation occlusion of the Internal Carotid Artery (ICA) terminus and/or Middle Cerebral Artery Main Stem (MCA M1) segment
  4. NIHSS score >6 at the time of randomization
  5. Ability to randomize within 24 hours of stroke onset
  6. Pre-stroke mRS score 0-1
  7. Ability to obtain signed informed consent

Imaging evidence of moderate-large infarct defined as:

  1. NCCT ASPECTS 2-5

Exclusion Criteria:

  • Females who are pregnant, or those of child-bearing potential with positive urine or serum beta Human Chorionic Gonadotropin (HCG) test
  • Known severe allergy (more than a rash) to contrast media uncontrolled by medications
  • Refractory hypertension (defined as persistent systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg)
  • CT evidence of the following conditions:
    • Midline shift or herniation
    • Evidence of intracranial hemorrhage
    • Mass effect with effacement of the ventricles
  • Computed Tomography Angiography (CTA) evidence suggestive of difficult endovascular access per the treating interventionalist
  • Presence of cervical ICA occlusion (e.g., related to atherosclerotic disease or dissection)
  • Rapidly improving neurological status prior to randomization to NIHSS <6
  • Bilateral strokes or multiple intracranial occlusions
  • Intracranial tumors
  • Known hemorrhagic diathesis, coagulation factor deficiency, or on anticoagulant therapy with an International Normalized Ratio (INR) of >3.0 or Partial Thromboplastin Time (PTT) >3 times of normal
  • Baseline platelet count <30,000 per microliter (µl)
  • Life expectancy less than 90 days prior to stroke onset
  • Participation in another randomized clinical trial that could confound the evaluation of the study
  • Any other condition (in the opinion of the site investigator) that precludes an endovascular procedure or poses a significant hazard to the patient if an endovascular procedure was performed

Global Impact of the COVID 19 Pandemic on Stroke Care: 1-year Follow-Up Study

Primary Investigator: Sushrut Dharmadhikari M.D.

National Clinical Trial Identifier: NCT04934020

Clinical Trial Link

Enrollment Status: Open

Clinical Trial Summary:

Phase: N/A

Funding: N/A

Disease: Ischemic Stroke, Hemorrhagic Stroke, COVID-19

Enrollment/Eligibility

Study Population

De-identified data from selected stroke metrics identified by ICD-10 codes from medical records of stroke patients in about 100 to 300 stroke centers in 6 continents will be analyzed.

Criteria

Inclusion Criteria:

  • Received stroke related care during the study period in one of the stroke centers across 6 continents

Exclusion Criteria:

  • None

For 2021 and 2022, BHMC-LR has a 0% infection rate related to EVD placement.

Join Commission Contact Information

For our Joint Commission Accredited locations: Little Rock, North Little Rock, Fort Smith, Van Buren, Arkadelphia and Heber Springs, you may also contact The Joint Commission at 1-800-994-6610 or by email at complaint@jointcommission.org.

Recent News & Resources